Agenus reports 72% complete pathologic response rate in Phase 2 colon cancer trial of BOT+BAL

By Public Technologies
  • Agenus reported early Phase 2 NEOASIS results showing most patients with locally advanced dMMR colon cancer had no cancer remaining at surgery.
  • The six-week preoperative botensilimab and balstilimab regimen met the study’s primary endpoint.
  • Results were presented at the ESMO Congress in Madrid on October 25, 2026.
  • Immune-related side effects were mostly mild or moderate and manageable; one patient’s severe colitis resolved with treatment.
  • Investigators are enrolling a rectal cancer cohort to assess whether the combination can help patients avoid surgery.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261025332881) on October 25, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.